NasdaqCM - Nasdaq Real Time Price ? USD BioLife Solutions, Inc. (BLFS) Follow Compare 25.75 +0.36 (+1.40%) As of 3:27 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BioLife Solutions, Inc. (NASDAQ:BLFS) Just Reported And Analysts Have Been Cutting Their Estimates BioLife Solutions, Inc. ( NASDAQ:BLFS ) just released its third-quarter report and things are looking bullish. The... Simply Wall St. ? 7 days ago BLFS +1.40% BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. PR Newswire ? 7 days ago BLFS +1.40% BioLife Solutions Third Quarter 2024 Earnings: Beats Expectations BioLife Solutions ( NASDAQ:BLFS ) Third Quarter 2024 Results Key Financial Results Revenue: US$30.6m (down 8.3% from 3Q... Simply Wall St. ? 8 days ago BLFS +1.40% BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ... BioLife Solutions Inc (BLFS) reports robust revenue growth and improved margins, while navigating challenges in its freezer business and macroeconomic risks. GuruFocus.com ? 9 days ago BLFS +1.40% BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates BioLife Solutions (BLFS) delivered earnings and revenue surprises of 77.78% and 21.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 9 days ago BLFS +1.40% BioLife Solutions Reports Third Quarter 2024 Financial Results BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced financial results for the three and nine months ended September 30, 2024 and updated revenue guidance for 2024. PR Newswire ? 9 days ago BLFS +1.40% BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approximately $10.4 million in revenue for the six months ended June 30, 2024. PR Newswire ? 10 days ago BLFS +1.40% BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024 BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general b PR Newswire ? 22 days ago BLFS +1.40% Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year? Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year. Zacks ? last month BLFS +1.40% LLY BioLife Solutions Inc (BLFS) Q2 2024 Earnings Call Highlights: Navigating Challenges with ... Despite a slight revenue dip, BioLife Solutions Inc (BLFS) showcases strong cell processing growth and improved margins, setting a positive outlook for the year. GuruFocus.com ? last month BLFS +1.40% Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. Zacks ? last month BLFS +1.40% Are Medical Stocks Lagging Eli Lilly (LLY) This Year? Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year. Zacks ? last month LLY BLFS +1.40% Disney upgraded, JPMorgan downgraded: Wall Street's top analyst calls Disney upgraded, JPMorgan downgraded: Wall Street's top analyst calls The Fly ? last month BLFS +1.40% Investing in BioLife Solutions (NASDAQ:BLFS) a year ago would have delivered you a 78% gain If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly... Simply Wall St. ? 2 months ago BLFS +1.40% BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2 Conestoga Capital Advisors, an asset management company, released its “Micro-Cap Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. The second quarter of 2024 may be regarded as a time of moderation. Economic indicators largely reflected slowing growth and easing inflation. The moderation theme also drives equity markets. Large-cap stocks, as measured […] Insider Monkey ? 3 months ago BLFS +1.40% ^RUT BioLife Solutions, Inc. (NASDAQ:BLFS): Is Breakeven Near? We feel now is a pretty good time to analyse BioLife Solutions, Inc.'s ( NASDAQ:BLFS ) business as it appears the... Simply Wall St. ? 3 months ago BLFS +1.40% BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates BioLife Solutions (BLFS) delivered earnings and revenue surprises of 57.14% and 19.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago BLFS +1.40% BioLife Solutions Reports Second Quarter 2024 Financial Results BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended June 30, 2024 and updated revenue guidance for 2024. PR Newswire ? 3 months ago BLFS +1.40% Is BioLife Solutions, Inc. (BLFS) the Best Organ Transplant and Diagnosis Stock to Buy Now? We recently compiled a list of the 10 Best Organ Transplant and Diagnosis Stocks To Buy Now. In this article, we are going to take a look at where BioLife Solutions, Inc. (NASDAQ:BLFS) stands against the other organ transplant and diagnosis stocks. In the dynamic landscape of healthcare, the importance of organ transplantation cannot be overstated. […] Insider Monkey ? 3 months ago BLFS +1.40% Is It Time To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)? BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it saw a significant share price... Simply Wall St. ? 3 months ago BLFS +1.40% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return BLFS S&P 500 YTD +58.43% +24.96% 1-Year +88.88% +31.34% 3-Year -49.32% +26.87%
